{"url_path":"/sec/txmd/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/25743/0001213900-26-055081-index.html","accession_number":"0001213900-26-055081","cik":"0000025743","ticker":"TXMD","issuer_name":"TherapeuticsMD, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/25743/0001213900-26-055081-index.html","primary_entity_key":"0000025743","primary_entity_name":"TherapeuticsMD, Inc."},"word_count":594,"has_tables":true,"body_markdown":"**Item 6. Exhibits**\n\n \n\n**Exhibit No.**\n \n**Description**\n\n \n \n\n3.1\n \n[Articles of Incorporation of AMHN, Inc. filed in the State of Nevada, dated July 20, 2010 (1)](https://www.sec.gov/Archives/edgar/data/25743/000119312510175462/dex35.htm)\n\n \n \n \n\n3.2\n \n[Bylaws of AMHN, Inc. (2)](https://www.sec.gov/Archives/edgar/data/25743/000119312510149198/ddef14c.htm)\n\n \n \n \n\n31.1†\n \n[Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a)](ea028698801ex31-1.htm)\n\n \n \n\n31.2†\n \n[Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a)](ea028698801ex31-2.htm)\n\n \n \n\n32.1††\n \n[Section 1350 Certification of Chief Executive Officer](ea028698801ex32-1.htm)\n\n \n \n\n32.2††\n \n[Section 1350 Certification of Principal Financial Officer](ea028698801ex32-2.htm)\n\n \n \n\n101†\n \nInline XBRL Document Set for the condensed consolidated financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q\n\n \n \n\n104†\n \nInline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set\n\n \n\n†\nFiled herewith.\n\n \n\n††\nFurnished herewith.\n\n \n \n\n(1)\nFiled as an exhibit to Form 10-Q for the quarter ended June 30, 2010 filed with the Commission on August 3, 2010 and incorporated herein by reference (SEC File No. 000-16731).\n\n \n \n\n(2)\nFiled as an exhibit to Definitive 14C Information Statement filed with the Commission on June 29, 2010 and incorporated herein by reference (SEC File No. 000-16731).\n\n30\n\n \n\n**Signatures**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nDate: May 12, 2026\nTherapeuticsMD, Inc.\n\n \n \n\n \n/s/ Marlan\nD. Walker\n\n \nMarlan D. Walker\n\n \nChief Executive Officer\n\n(Principal Executive Officer)\n\n \n\n \n/s/ Joseph\nZiegler\n\n \nJoseph Ziegler\n\n \nPrincipal Financial and Accounting Officer\n\n \n\n31\n\n \n\nhttp://fasb.org/srt/2026#ChiefExecutiveOfficerMember\n0000025743\nfalse\nQ1\n--12-31\n\n0000025743\n\n2026-01-01\n2026-03-31\n\n0000025743\n\n2026-05-11\n\n0000025743\n\n2026-03-31\n\n0000025743\n\n2025-12-31\n\n0000025743\n\n2025-01-01\n2025-03-31\n\n0000025743\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0000025743\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0000025743\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0000025743\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0000025743\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0000025743\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0000025743\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0000025743\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0000025743\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0000025743\n\n2024-12-31\n\n0000025743\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0000025743\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0000025743\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0000025743\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0000025743\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0000025743\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0000025743\n\n2025-03-31\n\n0000025743\n\ntxmd:MilestonePaymentsOneMember\ntxmd:MayneLicenseAgreementMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\ntxmd:MilestonePaymentsTwoMember\ntxmd:MayneLicenseAgreementMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\ntxmd:MilestonePaymentsThreeMember\ntxmd:MayneLicenseAgreementMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\ntxmd:RoyaltyRateOneMember\ntxmd:MaynePharmaMember\ntxmd:MayneLicenseAgreementMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\ntxmd:RoyaltyRateTwoMember\ntxmd:MaynePharmaMember\ntxmd:MayneLicenseAgreementMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\ntxmd:MayneLicenseAgreementMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\ntxmd:MayneLicenseAgreementMember\n\n2026-03-31\n\n0000025743\n\ntxmd:MayneLicenseAgreementMember\n\n2023-08-31\n2023-08-31\n\n0000025743\n\n2023-08-31\n2023-08-31\n\n0000025743\n\ntxmd:RubricCapitalManagementLPMember\n\n2023-05-01\n2023-05-01\n\n0000025743\n\ntxmd:RubricCapitalManagementLPMember\n\n2023-05-01\n\n0000025743\n\ntxmd:RubricCapitalManagementLPMember\n\n2023-06-29\n2023-06-29\n\n0000025743\n\ntxmd:RubricCapitalManagementLPMember\n\n2023-06-29\n\n0000025743\n\ntxmd:RubricCapitalManagementLPMember\n\n2023-11-15\n2023-11-15\n\n0000025743\n\ntxmd:RubricCapitalManagementLPMember\n\n2023-11-15\n\n0000025743\n\nus-gaap:PatentsMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\nus-gaap:PatentsMember\n\n2025-01-01\n2025-03-31\n\n0000025743\n\ntxmd:HormoneTherapyDrugPatentsMember\n\n2026-03-31\n\n0000025743\n\ntxmd:HormoneTherapyDrugPatentsMember\n\n2025-12-31\n\n0000025743\n\ntxmd:HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember\n\n2026-03-31\n\n0000025743\n\ntxmd:HormoneTherapyDrugPatentsAppliedAndPendingApprovalMember\n\n2025-12-31\n\n0000025743\n\ntxmd:IntangibleAssetsSubjectToAmortizationMember\n\n2026-03-31\n\n0000025743\n\ntxmd:IntangibleAssetsSubjectToAmortizationMember\n\n2025-12-31\n\n0000025743\n\nus-gaap:TrademarksAndTradeNamesMember\n\n2026-03-31\n\n0000025743\n\nus-gaap:TrademarksAndTradeNamesMember\n\n2025-12-31\n\n0000025743\n\ntxmd:MaynePharmaAgreementMember\n\n2022-12-30\n\n0000025743\n\ntxmd:MaynePharmaAgreementMember\n\n2023-09-30\n2023-09-30\n\n0000025743\n\ntxmd:MaynePharmaAgreementMember\n\n2023-12-31\n\n0000025743\n\nsrt:MaximumMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\nsrt:MinimumMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\ntxmd:ParagraphFourCertificationNoticeLetterMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\nus-gaap:PhantomShareUnitsPSUsMember\n\n2026-03-31\n\n0000025743\n\ntxmd:TwoThousandNineteenStockIncentivePlanMember\n\n2026-03-31\n\n0000025743\n\nus-gaap:PhantomShareUnitsPSUsMember\n\n2022-01-01\n2022-12-31\n\n0000025743\n\ntxmd:EmployeeStockPurchasePlanMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\ntxmd:EmployeeStockPurchasePlanMember\n\n2025-01-01\n2025-03-31\n\n0000025743\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2026-03-31\n\n0000025743\n\nus-gaap:WarrantMember\n\n2025-12-31\n\n0000025743\n\nus-gaap:WarrantMember\n\n2025-01-01\n2025-12-31\n\n0000025743\n\nus-gaap:WarrantMember\n\n2026-03-31\n\n0000025743\n\nus-gaap:WarrantMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\nus-gaap:StockOptionMember\n\n2024-12-31\n\n0000025743\n\nus-gaap:StockOptionMember\n\n2025-12-31\n\n0000025743\n\nus-gaap:StockOptionMember\n\n2025-01-01\n2025-12-31\n\n0000025743\n\nus-gaap:StockOptionMember\n\n2026-03-31\n\n0000025743\n\nus-gaap:StockOptionMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2024-12-31\n\n0000025743\n\ntxmd:RoyaltyRateOneMember\ntxmd:MayneLicenseAgreementMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\ntxmd:RoyaltyRateTwoMember\ntxmd:MayneLicenseAgreementMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\nus-gaap:EmployeeStockOptionMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\nus-gaap:EmployeeStockOptionMember\n\n2025-01-01\n2025-03-31\n\n0000025743\n\nus-gaap:PhantomShareUnitsPSUsMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\nus-gaap:PhantomShareUnitsPSUsMember\n\n2025-01-01\n2025-03-31\n\n0000025743\n\nus-gaap:WarrantMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\nus-gaap:WarrantMember\n\n2025-01-01\n2025-03-31\n\n0000025743\n\ntxmd:RubricCapitalManagementLPMember\nus-gaap:SeriesAPreferredStockMember\ntxmd:SubscriptionAgreementMember\n\n2022-12-30\n2022-12-30\n\n0000025743\n\ntxmd:RubricCapitalManagementLPMember\nus-gaap:SeriesAPreferredStockMember\ntxmd:SubscriptionAgreementMember\n\n2022-12-30\n\n0000025743\n\n2022-12-30\n2022-12-30\n\n0000025743\n\ntxmd:RubricCapitalManagementLPMember\n\n2023-06-29\n2023-06-29\n\n0000025743\n\ntxmd:RubricCapitalManagementLPMember\n\n2023-06-29\n\n0000025743\n\ntxmd:RubricCapitalManagementLPMember\n\n2023-11-15\n2023-11-15\n\n0000025743\n\ntxmd:RubricCapitalManagementLPMember\n\n2023-11-15\n\n0000025743\n\ntxmd:TheramexAndKnightMember\n\n2026-03-31\n\n0000025743\n\ntxmd:TheramexMember\n\n2026-03-31\n\n0000025743\n\ntxmd:MaynePharmaMember\n\n2026-03-31\n\n0000025743\n\ncountry:US\n\n2026-01-01\n2026-03-31\n\n0000025743\n\ncountry:US\n\n2025-01-01\n2025-03-31\n\n0000025743\n\nus-gaap:NonUsMember\n\n2026-01-01\n2026-03-31\n\n0000025743\n\nus-gaap:NonUsMember\n\n2025-01-01\n2025-03-31\n\nxbrli:shares\n\niso4217:USD\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure"}